Ocugen Inc. (OCGN) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, OCGN scores 25 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield -22.65%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). Every pillar sits in the bottom half of its range. The cash-generation and ownership-flow pillars are the weakest, meaning the company is consuming cash faster than it generates value and that its shareholder base is not showing strong conviction. For a prospective investor evaluating the stock today, the rating frames the risk profile as dominated by balance-sheet and cash-burn fragility rather than by a single identifiable catalyst. The balance-sheet pillar is the relatively less poor of the five, but a Piotroski F of 3/9 signals weak financial-health indicators. Any upside case would depend on developments the rating does not quantify. This is an analytical framing, not a personalized recommendation.

Ocugen Inc. (OCGN) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, its market capitalization is $0.3B. Per the news wire, the company's programs include three gene therapy programs for blindness, with key data expected in 2027 and 2028. Revenue in the reported periods is small relative to operating losses; the source data does not detail customers or the specific commercial model.

Per the SEC financials, the company reported operating and net losses in each period shown, with FY 2025 net loss of $-68.0M against revenue of $4.4M. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash is reported only for FY 2025 at $18.6M against debt of $27.5M, and the source data does not provide FY 2024 or FY 2023 cash figures.

• Insider selling: a headline reports the CEO sold $499,691 of company stock.
• Share sale proposal: a headline reports an officer proposes selling 525,991 shares through Merrill Lynch.
• Earnings: a transcript of the Q2 2026 earnings conference call is referenced.
• Clinical/program timing: key data from the three gene therapy programs for blindness is expected in 2027 and 2028.
• Options and coverage: options chain and analyst-prediction pages are referenced, without content in the source data.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The news wire items are all tagged YELLOW.

• What are the company's cash runway and funding requirements given FY 2025 FCF of $-57.1M and cash of $18.6M?
• What is the status and timing of the three gene therapy programs, and what are the 2027–2028 data expectations based on?
• What were the terms and purpose of the CEO's stock sale and the officer's proposed share sale?
• What do the FY 2024 and FY 2023 cash and debt balances look like, given they are missing from the source?
• What were the key takeaways from the Q2 2026 earnings call?